Sanofi Invests €1.3 Billion in New Insulin Manufacturing Plant in Frankfurt
Sanofi, insulin manufacturing, Frankfurt, €1.3 billion, BioCampus, digital solutions, diabetes patients, European supply chain
Pfizer Considers Facility Sale Amid GSK’s Administrative Breach in South Korea
Pfizer, facility sale, GSK, administrative breach, South Korea, pharmaceutical industry
Teladoc Posts $838M Loss in Q2, Announces Strategic Pivot for BetterHelp
Teladoc, BetterHelp, Q2 loss, strategic pivot, telehealth, virtual healthcare
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest
Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange
Otsuka Pharmaceutical Acquires Jnana Therapeutics for $800M to Develop PKU Treatment
Otsuka Pharmaceutical, Jnana Therapeutics, PKU, phenylketonuria, JNT-517, RAPID chemoproteomics platform, rare metabolic disorder, biotech acquisition
Valneva Invests $10M in LimmaTech for Clinical-Stage Shigella Vaccine
Valneva, LimmaTech, Shigella vaccine, clinical-stage, biotech, pharmaceuticals, vaccine development
FDA Approves Johnson & Johnson’s New Multiple Myeloma Therapy
FDA approval, Johnson & Johnson, multiple myeloma, CAR-T cell therapy, bispecific antibody, TALVEY, CARVYKTI, DARALEXASPRO
Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo Nordisk’s Semaglutide
Tirzepatide, Lilly, Phase III, Cardiovascular Study, Novo Nordisk, Semaglutide, Heart Failure, Obesity, Weight Loss